Sensus Healthcare (NASDAQ:SRTS) Price Target Raised to $12.00 at HC Wainwright

Sensus Healthcare (NASDAQ:SRTS) had its target price hoisted by HC Wainwright from $11.00 to $12.00 in a research note published on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

SRTS has been the subject of a number of other research reports. Lake Street Capital assumed coverage on Sensus Healthcare in a research note on Friday, January 31st. They issued a “buy” rating and a $18.00 price target for the company. Maxim Group boosted their target price on shares of Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Friday, November 15th.

Sensus Healthcare Trading Up 3.9 %

NASDAQ SRTS opened at $6.07 on Monday. The company has a market cap of $99.48 million, a price-to-earnings ratio of 15.18 and a beta of 1.24. The company has a 50 day moving average of $7.38 and a 200-day moving average of $6.89. Sensus Healthcare has a 1-year low of $2.91 and a 1-year high of $9.33.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. On average, equities research analysts forecast that Sensus Healthcare will post 0.71 earnings per share for the current year.

Institutional Trading of Sensus Healthcare

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC raised its stake in Sensus Healthcare by 8.5% during the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock worth $849,000 after acquiring an additional 11,525 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Sensus Healthcare by 128.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after purchasing an additional 93,511 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Sensus Healthcare during the 2nd quarter worth approximately $156,000. XTX Topco Ltd lifted its stake in Sensus Healthcare by 76.0% in the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after purchasing an additional 13,619 shares during the last quarter. Finally, Truvestments Capital LLC acquired a new stake in Sensus Healthcare in the third quarter valued at approximately $32,000. 25.30% of the stock is currently owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.